Journal Policies Research Articles

Issue Information

Journal of Policy and Practice in Intellectual DisabilitiesVolume 20, Issue 2 p. 133-135 Issue InformationFree Access Issue Information First published: 12 June 2023 https://doi.org/10.1111/jppi.12429AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. Volume20, Issue2June 2023Pages 133-135 RelatedInformation

Policy Approaches to Supporting Sustainable Journalism: An International Comparison of Public Policy Interventions Based on Platform Accountability and Public Expenditure

<p>新聞產業的商業模式因數位平台壟斷、新聞消費行為改變與廣告收入減少而崩壞。這不僅是新聞業生存的經濟問題，更是攸關民主正當性的政治問題。本文認為，僅靠新聞業自身的數位創新與轉型無法解決這個危機，政府必須透過公共政策介入。本文提出兩種解決途徑：平台問責與公共預算。除了進行跨國比較外，本文還評估這兩種途徑各自的方案，分析優劣，並探討跨國實踐經驗對臺灣新聞政策的啟示。</p> <p> </p><p>The collapse of the news industry’s business model is due to the monopolization of digital platforms, changes in news consumption behavior, and a reduction in advertising revenue. This is not only an economic matter concerning the survival of the news industry, but also a political matter concerning the legitimacy of democracy. This paper argues that the crisis in the news industry cannot be resolved solely through digital innovation and transformation, but instead that urgent government intervention through appropriate public policy measures is required. This paper also proposes two solutions to the crisis: platform accountability and public expenditure. In addition to conducting international comparisons, this article evaluates the various options contained in each solution, analyzes their advantages and disadvantages, and discusses the implications of international practices and experience for Taiwan’s journalism policy.</p> <p> </p>

A global network of scholars? The geographical concentration of institutes in migration studies and its implications

The study of international migration and responses to it has experienced rapid growth in the last three decades: an institutionalisation of migration studies. This paper identifies and specifies infrastructural and semantic elements of institutionalisation by establishing a global Directory of Migration Research Institutions identifying 282 institutes focused on migration research that were operative between 1945 and 2020. We observe a clear geographical concentration in the Americas and Europe and find that most institutes are in countries with higher economic development (GDP) and net immigration (not emigration). Using this evidence, we suggest that the institutionalisation of migration studies is driven by concerns and ideas produced in high-income ‘destination’ countries. We thus show that uneven knowledge production in migration studies is not only caused by exclusive categories, language, or journal policies, but also by a structural problem at an earlier stage: because of fewer resources invested in the creation of institutionalised academic knowledge structures, lower income countries have fewer possibilities to shape the semantic features of the field of migration studies, by which we mean the identification of subjects of interest, concepts, narratives, and priorities.

How reproducible and reliable is geophysical research?

Geophysical research frequently makes use of agreed-upon methodologies, formally published software, and bespoke code to process and analyse data. The reliability and repeatability of these methods is vital in maintaining the integrity of research findings and thereby avoiding the dissemination of unreliable results. In recent years there has been increased attention on aspects of reproducibility, which includes data availability, across scientific disciplines. This review considers aspects of reproducibility of geophysical studies relating to their publication in peer reviewed journals. For 100 geophysics journals it considers the extent to which reproducibility in geophysics is the focus of published literature. For 20 geophysical journals it considers a) journal policies on the requirements for providing code, software, and data for submission; and b) the availability of data and software associated for 200 published journal articles. The findings show that: 1) between 1991 and 2021 there were 72 articles with reproducibility in the title and 417 with reliability, with an overall increase in the number of articles with reproducibility or reliability as the subject over the same period; 2) while 60% of journals have a definition of research data, only 20% of journals have a requirement for a data availability statement; and 3) despite ~86% of sampled journal articles including a data availability statement, only 54% of articles have the original data accessible via data repositories or web servers, and only 49% of articles name software used. It is suggested that despite journals and authors working towards improving the availability of data and software, frequently they are not identified, or easily accessible, therefore limiting the possibility of reproducing studies.

Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. May 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02804 Journal of Clinical Oncology - published online before print May 5, 2023 PMID: 37146425 Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Duke Cancer Institute, Division of Medical Oncology, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02804 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis phase III, noninferiority study1 investigated the novel chemotherapy combination of cisplatin and pemetrexed compared with the standard combination of cisplatin and gemcitabine demonstrating that survival was noninferior between the two platinum-based combinations, and a lower rate of grade 3 or 4 neutropenia and febrile neutropenia was observed with cisplatin and pemetrexed. However, cisplatin and pemetrexed demonstrated a superior survival in patients with adenocarcinoma and large cell histologies and inferior survival in patients with squamous histology, and after this trial, the use of pemetrexed was restricted to patients with nonsquamous histology.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Balkan Medical Journal Policy on the Use of Chatbots in Scientific Publications

Balkan Medical Journal Policy on the Use of Chatbots in Scientific Publications

Reports of practitioners’ use of public affairs faculty published research

ABSTRACT Using a unique dataset built around published papers in top quality public policy, public administration and program evaluation journals, we find that 29.7% of respondent authors indicate that the knowledge from their articles was used by policymakers or public administrators. These data are used to test for different patterns of use for policy vs management knowledge. Findings suggest that journal quality positively affects policy use but negatively affects management use and that topics suggested by practitioners affect management use but not policy use. The researchers’ degree of motivation to have their work used is important in both types of knowledge use. Overall, the results suggest there may be greater spillovers to practical use derived from standard academic publishing pursuits than generally believed.

Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. April 26, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02790 Journal of Clinical Oncology - published online before print April 26, 2023 Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Duke Cancer Institute, Durham, NC https://doi.org/10.1200/JCO.22.02790 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis randomized phase II trial1 compared carboplatin and paclitaxel alone (the control arm) with carboplatin and paclitaxel with bevacizumab at two doses in patients with non–small-cell lung cancer (NSCLC). Bevacizumab 15 mg/kg once every 3 weeks was the dose selected for future clinical trials, and an excessive rate of toxicity was observed in the subset of patients with squamous histology, leading to the exclusion of patients with NSCLC with squamous histology from future trials of bevacizumab in NSCLC.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Authors' conflicts of interest in Nepalese healthcare journals.

Most biomedical journals now require authors to declare their conflicts of interest (COI), especially financial ones, before they accept the manuscript for submission. This study aims to examine the COI policies of Nepalese healthcare journals. The sample constituted journals indexed in Nepal Journals Online (NepJOL) as of June 2021. Of the 68 that met our inclusion criteria, 38(55.9%) journals endorsed the COI policy of the International Committee of Medical Journal Editors. Thirty-six (52.9%) journals had a policy for reporting the COI. Financial COI was the only type of COI mentioned. All journals in Nepal are encouraged to request the authors to declare the COI for better transparency.

Training and capacity building of young water professionals—role of an innovative and transformative program for sustainable water futures

AbstractWater management has become quite a complex task because of population pressure, climate change, and urbanization. Future young water professionals (YWPs) need to be capable of working with real‐world situations, and they need to be trained suitably so that they can effectively communicate with decision‐makers and enable innovative ideas to be adopted in policy development and actions on the ground. To get the ideas converted into actions, we need YWPs who are well‐trained not only in water science and engineering but also in social, economic, governance, policy, and other related aspects. Overall, well‐designed transdisciplinary training can help YWPs to bring new thinking and leadership in their workplace, including water governance, stakeholder involvement, critical thinking, problem analysis, and effective communication in various situations. Furthermore, such training can help YWPs develop their vision and capacity for more effective planning, design, implementation, and management of water projects and initiatives. As part of their training, YWPs need to develop their competencies, namely, problem‐solving, transdisciplinary and systemic thinking, and effective communication, through working on real‐world projects of selected clients. The next issue of World Water Policy Journal will be a Special Issue focusing on the work of YWPs involved in two initiatives in South Asia. Activities through the Australia–India Water Centre Program for capacity building for Indian YWPs in Sustainable Water Futures will be one of the initiatives presented.

Policies Affecting Pregnant Women with Substance Use Disorder

Policies Affecting Pregnant Women with Substance Use Disorder

Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. April 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02720 Journal of Clinical Oncology - published online before print April 17, 2023 PMID: 37068376 Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Division of Medical Oncology, Duke Cancer Institute, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02720 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2003, Vogelzang et al1 published a phase III trial, which demonstrated a superior overall survival, time to progression, and response rate with cisplatin and pemetrexed compared with cisplatin in patients with malignant pleural mesothelioma. At the time this trial was performed, there were doubts about the efficacy of chemotherapy in this disease, and this trial validated chemotherapy as an effective treatment, and platinum-pemetrexed became the standard first-line treatment for the next 2 decades.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Pemetrexed and Cisplatin in MesotheliomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Data and reproducibility. Interpretation of international guidelines and journals’ best policies and practices

Relevance. The 2022 Update of the COPE, DOAJ, OASPA, and WAME joint guidelines on The Principles of Transparency and Best Practice in Scholarly Publishing encourages journals to establish their own policy in “data sharing and reproducibility” (DS&R). However, this document neither provides detailed recommendations / templates nor explains the reproducibility crisis phenomenon.Objectives. To analyze and interpret the international guidelines, the best practices of global publishers and journals, as well as typical mistakes and experience of selected Russian journals, to help a journal develop its own DS&R policy and its implementation.Materials and methods. The analysis of various sources (literature, reporting guidelines, data repositories), policies of 83 Russian university journals, as well as policies of the top 5 international publishers and their journals. Interviews with 6 editors-in-chief of Russian journals regarding DS&R.Results. All the top 5 global publishers in their DS&R policy adapt the TOP Guidelines and offer their own data sharing statement templates. Discussion and interpretations. The author suggests Russian translation of the TOP Guidelines and the main templates (e.g., data sharing statement). He also discusses 9 best journal policies and practices (including pre-registration studies).Conclusions. Numerous international sources, as well as the experience of selected Russian journals, demonstrate that the implementation of the DS&R policy increases articles citation (averagely by 25.3%), the growth of journal’s bibliometric and altmetric indicators, and also contributes to the trust of the target audience. As a result, it strengthes the journal portfolio to enable publishing articles well ahead of schedule. However, only the declarative statement of DS&R policies by journals without proper implementation does not bring tangible benefits to the journals.

Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. April 05, 2023 Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. April 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00153 Journal of Clinical Oncology - published online before print April 5, 2023 PMID: 37018918 Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma Michael A. Carducci, MD1,2xMichael A. CarducciSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD https://doi.org/10.1200/JCO.23.00153 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2009, Motzer et al1 demonstrated an overall survival advantage for sunitinib over interferon-α in metastatic clear cell renal carcinoma; in 2010, Sternberg et al2 demonstrated an 8-month improvement in progression-free survival over placebo in the same patient population as sunitinib. These two reports laid the foundation for vascular endothelial growth factor tyrosine kinase inhibition therapy in renal cancer and forming the building blocks for immune checkpoint combination therapies now used in clinical practice further extending the lives of patients with advanced renal cell carcinoma.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell CarcinomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael A. CarducciThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Pfizer, Acrivon Therapeutics, AstraZeneca, SanofiResearch Funding: Pfizer (Inst), Arcus Biosciences (Inst), Merck (Inst), Celgene/Bristol Myers Squibb (Inst)No other potential conflicts of interest were reported. Companion Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Cryptococcal meningitis with suspected concomitant neurosyphilis in an immunocompetent individual: A diagnostic dilemma

No abstract available.

The trouble with normalisation: Transformations to hepatitis C health care and stigma in an era of viral elimination.

Modern health-care systems have customarily approached hepatitis C in ways that resemble the public health approach to HIV/AIDS known as 'HIV exceptionalism'. HIV exceptionalism describes the unusual emphasis on privacy, confidentiality and consent in approaches to HIV and was partly developed to address HIV/AIDS-related stigma. In the case of hepatitis C, exceptionalist approaches have included diagnosis and treatment by specialist physicians and other 'boutique' public health strategies. The recent availability of highly effective, direct-acting antivirals alongside goals to eliminate hepatitis C have heralded dramatic changes to hepatitis C health care, including calls for its 'normalisation'. The corollary to exceptionalism, normalisation aims to bring hepatitis C into routine, mainstream health care. This article draws on interviews with stakeholders (n=30) who work with hepatitis C-affected communities in policy, community, legal and advocacy settings in Australia, alongside Fraser etal.'s (2017, International Journal of Drug Policy, 44, 192-201) theorisation of stigma, and Rosenbrock etal.'s (1999, The AIDS policy cycle in Western Europe: from exceptionalism to normalisation. WZB Discussion Paper, No. P 99-202) critique of normalisation to consider the perceived effects of hepatitis C normalisation. Stakeholders described normalisation as a stigma-reducing process. However, they also expressed concerns about the ongoing stigma and discrimination that is not ameliorated by normalisation. We suggest that in centring normalisation, changes in health care may exaggerate the power of technological solutions to transform the meanings of hepatitis C.

Exploring Nigeria’s Public Projects Prospects for the Good of Nigerians

Public projects that should facilitate wellbeing of Nigerians have suffered setbacks and not been able to do so. This study is a descriptive type and discussed the forces of projects failure, intrigues of public officers that subvert project outcomes, the expected roles of state actors in project pursuits, and prospects for public projects in Nigeria. The study found that paucity of funds, policy summersault, and inflation of projects costs, poor delivery of projects or outright abandonment by contractors, attitudes of the ruling regime, its successor and beneficiaries are some of the forces that obstruct public projects. The study also found that corruption, use of direct labor, connivance; party politics, poor focus and maintenance, personalization of public project, misplaced priority are some of the intrigues of project initiators that subvert project outcomes in Nigeria. The study also found that numerous skilled bureaucrats, due process, procurement system, and supremacy of the constitution, multi-party politics, and the presidential system of government with democratic system that Nigeria practices are some of the opportunities open to the country on its public projects fortune. This study made use of secondary data that was sourced from journal articles, online materials, government gazettes, policy documents, and other publications. The data was content analyzed thematically. The study concluded that members of the public need to make attainable gains from numerous public project opportunities. Keywords: project initiator, opportunities, public projects, masses, wellbeing of Nigerians DOI: 10.7176/PPAR/13-3-01 Publication date: April 30 th 2023

Survey and analysis of the data policy of the journals listed in the Excellence Action Plan for China's STM Journals Program for example

As an important output of scientific research, scientific data play an important role in scholarly communication. The establishment of the data policy of STM journals is of great significance to promote the data sharing, data reuse, data citation and scientific research evaluation. In this paper, by means of literature research and online research and based on the information published on journal websites, we surveyed the data policies operation status of 302 STM journals that were selected as the leading journals, key journals, and echelon journals in the Excellence Action Plan for China's STM Journals. Then we statistically analyzed the data policy setting, and the features of the policy, such as classification types, data availability, and data citation. The survey shows the current practice progress of China’s high-level STM journals related to scientific data publishing. Among the statistical journal sources, 81.82% of leading journals, 62.07% of key journals, 34.67% of echelon journals and 69.23% of high-starting new journals have formulated relevant data policies. According to survey results, the publication of data in STM journals has been widely recognized as one of the effective ways to promote scientific data sharing. Presently, all major publishing institutions have developed relevant data policies. Compared with the international counterparts, the data publishing of China’s STM journals still has a long way to go in industry recognition and framework strategy, and it is urgent to develop a universal data policy framework for different journals and publishers.

Hysteroscopic resection of cervical ectopic pregnancy: A case report

No abstract available

Factors of Indonesia Economic Growth (2017-2022)

Economic growth is measured by changes in a country’s Gross Domestic Product (GDP), which can be unraveled into the population and economic elements. This research is conducted to find trends and identify publications on economic growth in Indonesia in the 2017–2022 period. The data collection techniques by downloading files from the Scopus database to see publication trends with the highest number of documents, ranking classifications of institutions or universities, journals, and documents, and using shared keywords. The method used is bibliometric analysis. A total of 168 documents collected from the Publish or Perish (PoP) application using the Scopus database were combined into one file in RIS format and entered into the VOSviewer application to obtain network visualization and overlay visualization. The study results show that the trend of publications related to economic growth in Indonesia for the last six years has decreased yearly. The highest number of documents is in the “International Journal of Energy Economics and Policy,” with 20 documents, followed by the Haseeb (2019) article, totaling 120 citations. Based on the keywords that have been visualized, several keywords are factors of economic growth in Indonesia from 2017 to 2022, namely Energy Consumption, Investment, CO2 Emissions, Education, GDP, Inflation, FDI, Exchange Rate, Export, Government Expenditure, Income Inequality, Inequality, Human Capital, Human Development Index, and Sustainable Development.